Prevention of Staphylococcus aureus infections: Advances in vaccine development

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 669-676

  Shinefield, Henry R ^a,b   Black, Steven ^c  

^a University of California School of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Antibiotic resistant; Bacterial interference; Staphylococcus aureus; Vaccine; Virulence factors

Indexed keywords

ADHESIN; ALPHA TOXIN; ALTASTAPH; BACTERIAL POLYSACCHARIDE; CLUMPING FACTOR MONOCLONAL ANTIBODY; ELASTASE; ENTEROTOXIN; FIBRONECTIN BINDING PROTEIN; HEMOLYSIN; HYALURONIDASE; INACTIVATED VACCINE; LEUKOCIDIN; LIPOTEICHOIC ACID MONOCLONAL ANTIBODY; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MUTANT TOXIC SHOCK SYNDROME TOXIN 1; PHOSPHOLIPASE C; PROTEIN A; PSEUDOMONAS EXOTOXIN; RECOMBINANT PSEUDOMONAS AERUGINOSA EXOTOXIN A; STAPHVAX; STAPHYLOCOCCUS VACCINE; TEICHOIC ACID; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBODY RESPONSE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; DRUG SCREENING; DRUG TARGETING; HOST RESISTANCE; HUMAN; IMMUNIZATION; INFECTION PREVENTION; MEDICAL EXPERT; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VACCINATION; VIRUS STRAIN;

ANIMALS; BACTERIAL CAPSULES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INFANT; INFANT, NEWBORN; MULTICENTER STUDIES; POLYSACCHARIDES, BACTERIAL; RANDOMIZED CONTROLLED TRIALS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINATION; VACCINES, CONJUGATE;

EID: 27444433094     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.669     Document Type: Review

References (47)

1. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22), 2976-2984 (2003).
2. Gregerson A, Daum RS. Staphylococcus aureus Vaccine In: Vaccines. S Plotkin, W Orenstein (Eds.). Saunders, PA, USA 1347-1355 (2004).
3. Wertheim HF, Vos MC, Ott A et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers Lancet 364(9435), 703-705 (2004).
4. Nouwen JL, Fieren MW, Snijders S et al. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int. 67(3), 1084-1092 (2005).
5. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32(1), 108-115 (2001).
6. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49(3), 467-470 (2002).
7. Ament PW, Jamshed N, Home JP. Linezolid: its role in die treatment of Gram-positive, drug-resistant bacterial infections. Am. Fam. Physician 65(4), 663-670 (2002).
8. Shinefield HR. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine (Epub. ahead of print) (2005).
9. Menzies BE, Kernodle DS. Passive immunization with antiserum to a nontoxic α-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect. Immun. 64(5), 1839-1841 (1996).
10. Aly R, Shinefield HR, Litz C et al. Role of teichoic acid in the binding of Staphylococcus aureus to nasal epithelial cells. J. Infect. Dis. 141(4), 463-465 (1980).
11. Weidenmaier C, Kokai-Kun JF, Kristian SA et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nature Med. 10(3), 243-245 (2004). Recent paper confirming earlier findings that teichoic acids displayed on the surface of staphylococci are critical factors for staphylococcal colonization.
12. Moreillon P, Entenza JM, Francioli P et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immun. 63(12), 4738-4743 (1995).
13. Hall AE, Domanski PJ, Patel PR et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. 71(12), 6864-6870 (2003).
14. Shinefield HR, Ribble JC, Boris M et al. Bacterial interference between strains of S. aureus. Ann. NY Acad. Sci. 236, 444-455 (1974).
15. Steele RW. Recurrent staphylococcal infection in families. Arch. Dermatol. 116(2), 189-190 (1980).
16. Nouwen J, Fieren M, Snijders S et al. Bacterial interference therapy with Staphylococcus aureus 502A for eradication of wild type S. aureas. 44th ICAAC, October 30-November 2, DC, USA (2004).
17. Sprunt K, Leidy G, Redman W. Abnormal colonization of neonates in an ICU: conversion to normal colonization by pharyngeal implantation of α-hemolytic streptococcus strain 215. Pediatr. Res. 14(4 Pt. 1), 308-313 (1980).
18. Houck PW, Nelson JD, Kay JL. Fatal septicemia due to Staphylococcus aureus 502A. Report of a case and review of the infectious complications of bacterial interference programs. Am. J. Dis. Child. 123(1), 45-48 (1972).
19. Drutz DJ, Van Way MH, Schaffner W et al. Bacterial interference in the therapy of recurrent staphylococcal infections. Multiple abscesses due to the implantation of the 502A strain of Staphylococcus. N. Engl. J. Med. 275(21), 1161-1165 (1966).
20. Weidenmaier C, Peschel A, Xiong YQ et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191(10), 1771-1777 (2005).
21. Weisman LE, Thackray HM, Gracia-Prats JA et al. Phase I/II double-blind, placebo-controlled, dose escalation, safety and pharmacokinetics study in very low birth weight neonates of BSYX-A110, an antiStaphylococcal monoclonal antibody for the prevention of Staphylococcal bloodstream infections (Abstract LB14). Pediatric Academic Societies Annual Meeting. CA, USA, May 1-4 (2004).
22. Stinson JR, Lopez V, Grinberg L et al. The murine antibody response to lipoteichoic acid: linkage between innate and adaptive immunity. (In Press) (2005).
23. Menzies BE. The role of fibronectin binding proteins in the pathogenesis of Staphylococcus aureus infections. Curr. Opin. Infect. Dis. 16(3), 225-229 (2003).
24. Novick RP, Ross HF, Projan SJ et al. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J. 12(10), 3967-3975 (1993).
25. Ji G, Beavis R, Novick RP. Bacterial interference caused by autoinducing peptide variants. Science 276(5321), 2027-2030 (1997).
26. Mayville P, Ji G, Beavis R et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. NatlAcad. Sci. USA 96(4), 1218-1223 (1999).
27. Lyon GJ, Mayville P, Muir TW et al. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. Proc. Natl Acad. Sci. USA 97(24), 13330-13335 (2000). One of a series of papers identifying a molecular correlate of bacterial interference, and extending the finding to designing a global inhibitor of staphylococcal attachment.
28. Ghiselli R, Giacometti A, Cirioni O et al. RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. Eur. J. Vasc. Endovasc. Surg. 27(6), 603-607 (2004).
29. Cirioni O, Giacometti A, Ghiselli R et al. Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides. Circulation 108(6), 767-771 (2003).
30. Hume EB, Dajcs JJ, Moreau JM et al. Immunization with α-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect. Immun. 68(10), 6052-6055 (2000).
31. Adlam C, Ward PD, McCartney AC et al. Effect immunization with highly purified α- and β-toxins on staphylococcal mastitis in rabbits. Infect. Immun. 17(2), 259-256 (1977).
32. Poole-Warren LA, Hallett MD, Hone PW et al. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. Clin. Nephrol. 35(5), 198-206 (1991).
33. Prevost G, Couppie P, Prevost P et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J. Med. Microbiol. 42(4), 237-245 (1995).
34. Diep BA, Sensabaugh GF, Somboona NS et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J. Clin. Microbiol. 42(5), 2080-2084 (2004).
35. Gampfer J, Thon V, Guile H et al. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine 20(9-10), 1354-1364 (2002).
36. Hu DL, Omoe K, Sasaki S et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J. Infect. Dis. 188(5), 743-752 (2003).
37. Roghmann M, Taylor KL, Gupte A et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp. Infect. 59(1), 27-32 (2005).
38. Benjamin D, Schelonka R, White R et al. A blinded, randomized, multicenter study to assess the safety of an intravenous Staphylococcus aureus immune globulin (human) [Altastaph™] In: Very-low-birth-weight (VLBW) neonates. Pediatric Academic Societies Annual Meeting. DC, USA (2005) (Abstract 2341).
39. Fattom AI, Sarwar J, Ortiz A et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64(5), 1659-1665 (1996).
40. Fattom A, Schneerson R, Watson DC et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus Type 5 and Type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61(3), 1023-1032 (1993).
41. Welch PG, Fattom A, Moore J Jr. et al. Safety and immunogenicity of Staphylococcus aureus Type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Am. Soc. Nephrol. 7(2), 247-253 (1996).
42. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl J. Med. 346(7), 491-496, (2002). Phase III clinical trial of a staphylococcal vaccine. StaphVAX®, demonstrated efficacy for 32 weeks in patients receiving hemodialysis.
43. Fattom A, Fuller S, Propst M et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23(5), 656-663 (2004). Follow-on study of StaphVAX, showing that high antibody levels against capsular polysaccharides types 5 and 8 could be restored with a booster dose.
44. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99(10), 6573-6578 (2002).
45. Weichhart T, Horky M, Sollner J et al. Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. Infect. Immun. 71(8), 4633-4641 (2003).
46. Meinke A, Henics T, Hanner M et al. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 23(17-18), 2035-2041 (2005). Genomics approach used to identify potential targets for new staphylococcal vaccines.
47. Holden MT, Feil EJ, Lindsay JA et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl Acad. Sci. USA 101(26), 9786-9791 (2004).